- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Rozuvastatin and metformin combo effectively lowers abdominal obesity and cholesterol in women: Study
![Rozuvastatin and metformin combo effectively lowers abdominal obesity and cholesterol in women: Study Rozuvastatin and metformin combo effectively lowers abdominal obesity and cholesterol in women: Study](https://medicaldialogues.in/h-upload/2020/10/06/750x450_135415-obesity-in-women.webp)
USA: A recent study suggests that the combination of rozuvastatin and metformin is best for the management of abdominal obesity with hypercholesterolemia. The study was published online by the18th annual WCIRDC (World Congress Insulin Resistance Diabetes & Cardiovascular Disease).
Abdominal obesity is the basic diagnostic criteria for metabolic syndrome. The effective correction of abdominal obesity can prevent metabolic syndrome in its early stages. Keeping this in mind, K.Tchaava, Tbilisi State Medical University, Tbilisi, Georgia, and colleagues set out to compare the efficacy of combined treatment with of Rozuvastatin (Rozuvastatin Denk) 10mg. and Metformin and Metformin as monotherapy after 10 months in women with abdominal obesity.
20 patients with abdominal obesity were given monotherapy with metformin 850 mg/day, 30 patients were prescribed combination therapy (Rozuvastatin (Rozuvastatin Denk) 10mg. and Metformin 850 mg/day). The efficacy and safety of this therapy were compared after 10 months.
The study authors found that the combination of Rozuvastatin (Rozuvastatin Denk) and metformin in low doses (n=30) for 10 months more effectively reduced body mass index, improved lipid range levels (total Cholesterol decreased from 5,7mmol/l to 4,7 mmol/l).
"In management of abdominal obesity with hypercholesterolemia best is combination therapy with of Rozuvastatin and Metformin, the authors concluded.
About Rosuvastatin
Rosuvastatin belongs to a group of drugs known as "statins and is used along with a proper diet to help lower "bad" cholesterol and fats (such as LDL, triglycerides) and raise "good" cholesterol (HDL) in the blood. Lowering "bad" cholesterol and triglycerides and increasing "good" cholesterol reduces the risk of heart disease and helps in preventing strokes and heart attacks. " It works by reducing the amount of cholesterol made by the liver.
About Metformin
Metformin is a drug used for the treatment of type 2 diabetes. It is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. Metformin works by helping to restore the body's proper response to the insulin naturally produced by the body. Proper control of diabetes may also reduce the risk of a heart attack or stroke.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751